While three early clinical trials of these drugs did not find they led to health improvements for participants, further trials are getting more intentional in targeting viral persistence. The post No “easy home runs”: Early Long COVID trials of Paxlovid and monoclonal antibodies failed, but the treatments still have potential first appeared on The Sick Times.
